BATF2是一种对谷氨胺有反应的瘤抑制剂,用于I型干扰素依赖的抗瘤免疫
Wang Gong1,2, Hülya F Taner3, Yuesong Wu4
1Department of Head and Neck Surgery, the University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Nature communications
|December 28, 2025
概括
谷氨酸在头癌中抑制瘤抑制剂BATF2,促进免疫逃生. 恢复BATF2可以增强抗瘤免疫力,控制癌症的进展.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 瘤抑制剂在癌症中至关重要,但有些是由代谢线索而不是突变抑制的.
- 头部和部状细胞癌 (HNSCC) 在癌症治疗中存在独特的挑战.
研究的目的:
- 在HNSCC中识别和描述一种新的瘤抑制剂,BATF2.
- 阐明代谢线索,特别是谷氨酸在调节BATF2表达和功能的作用.
- 研究BATF2对抗瘤免疫力和癌症进展的影响.
主要方法:
- 表观遗传学分析以确定BATF2沉声机制.
- 在BATF2表达,干扰素特征和STING通路激活之间进行相关性研究.
- 代谢分析和饮食干预措施 (富含谷氨酸的饮食).
- 在体内研究中使用合成,正位和致癌诱导的HNSCC模型.
- 免疫细胞透 (CD206+,CD8+T细胞) 和T细胞耗尽标记物的分析.
主要成果:
- 在HNSCC中,BATF2是由谷氨酸在表观遗传上沉默的.
- BATF2表达与I型干扰素和Th1特征有很强的相关性,其酸化促进了STING的寡合化.
- 高谷氨胺水平或BATF2缺乏导致对I型干扰素产生不利的代谢特征,并损害STING介导的瘤控制.
- 癌细胞特定的BATF2表达促进T细胞效应器功能,减少疲劳,并诱导HNSCC排斥.
- 主体BATF2缺陷通过增加CD206+髓状细胞和减少CD8+T细胞来加速癌症的开始.
结论:
- 在HNSCC中,BATF2充当瘤抑制剂,其损失由瘤微环境 (TME) 中代谢线索介导.
- 对BATF2的代谢失调有助于癌症免疫逃逸.
- 针对BATF2或调节谷氨胺代谢可能为HNSCC提供新的治疗策略.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K


